RESUMEN
The importance of speed to clinic for medicines that may address unmet medical needs puts pressure on product development timelines. Historically, both toxicology and first-in-human clinical materials are generated using the same clonal-derived cells to ensure safety and minimize any development risks. However, cell line development with single cell cloning is time consuming, and aggravated by the time needed to screen for a lead clone based on cell line stability and manufacturability. In order to achieve faster timelines, we have used pools of up to six clones for earlier production of drug substance for regulatory filing-enabling toxicology studies, and then the final single clone was selected for production of clinical materials. This approach was enabled by using platform processes across all stages of early development, including expression vectors, host cell lines, media, and production processes. Through comprehensive cell culture and product quality analysis, we demonstrated that the toxicology material was representative of the clinical material for all six monoclonal antibody programs evaluated. Our extensive development experience further confirmed that using a pool of clones for toxicology material generation is a reliable approach to shorten the early development timeline.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Células Clonales/inmunología , Evaluación Preclínica de Medicamentos/métodos , Drogas en Investigación/metabolismo , Proteínas Recombinantes/inmunología , Animales , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales/toxicidad , Células CHO , Células Clonales/efectos de los fármacos , Cricetinae , Cricetulus , Drogas en Investigación/uso terapéutico , Drogas en Investigación/toxicidad , Humanos , Proteínas Recombinantes/uso terapéutico , Proteínas Recombinantes/toxicidad , Pruebas de Toxicidad/métodosAsunto(s)
Sistemas de Liberación de Medicamentos/tendencias , Drogas en Investigación/administración & dosificación , Drogas en Investigación/síntesis química , Enfermedades Neurodegenerativas/tratamiento farmacológico , Animales , Sistemas de Liberación de Medicamentos/métodos , Evaluación Preclínica de Medicamentos/métodos , Drogas en Investigación/metabolismo , Humanos , Enfermedades Neurodegenerativas/metabolismoRESUMEN
Drug-induced liver injury (DILI) is a major concern for drug developers, regulators and clinicians. It is triggered by drug and xenobiotic insults leading to liver impairment or damage, in the worst-case liver failure. In contrast to acute "intrinsic" hepatotoxicity, DILI typically manifests in a very small subset of the population under treatment with no clear dose relationship and inconsistent temporal patterns and is therefore termed an idiosyncratic event. Involved are multifactorial, compound-dependent mechanisms and host-specific factors, making the prediction in preclinical test systems very challenging. While preclinical safety studies in animals usually are able to capture direct, acute liver toxicities, they are less predictive for human DILI, where specific, human-derived in vitro models can potentially close the gap. On one hand, mechanistic approaches addressing key mechanisms involved in DILI in well-characterized and standardized in vitro test systems have been developed. On the other hand, co-cultures of different cell types, including patient- and/or stem cell-derived cells, in a three-dimensional setup allow for prolonged incubations and multiplexed readouts. Such complex setups might better reflect multifactorial human DILI. One major challenge is that for many compounds with human DILI the underlying mechanisms are not yet fully understood, complicating establishment and validation of predictive cellular tools. A tiered approach including rapid mechanism-based in vitro screens followed by confirmatory tests in more physiologically relevant models might allow minimizing DILI risk early on in vitro. Such complex, integrated approaches will gain from larger collaborations in multidisciplinary groups bringing existing knowledge and state-of-the-art technology together.
Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/prevención & control , Evaluación Preclínica de Medicamentos , Drogas en Investigación/efectos adversos , Modelos Biológicos , Xenobióticos/toxicidad , Alternativas a las Pruebas en Animales/tendencias , Animales , Línea Celular , Células Cultivadas , Técnicas de Cocultivo , Biología Computacional , Evaluación Preclínica de Medicamentos/tendencias , Drogas en Investigación/metabolismo , Sistemas Especialistas , Hepatocitos/citología , Hepatocitos/efectos de los fármacos , Hepatocitos/metabolismo , Humanos , Reconocimiento de Normas Patrones Automatizadas/tendencias , Reproducibilidad de los Resultados , Investigación Biomédica Traslacional/tendencias , Xenobióticos/metabolismoRESUMEN
Sixteen training compounds selected in the IMI MIP-DILI consortium, 12 drug-induced liver injury (DILI) positive compounds and 4 non-DILI compounds, were assessed in cryopreserved primary human hepatocytes. When a ten-fold safety margin threshold was applied, the non-DILI-compounds were correctly identified 2h following a single exposure to pooled human hepatocytes (n=13 donors) in suspension and 14-days following repeat dose exposure (3 treatments) to an established 3D-microtissue co-culture (3D-MT co-culture, n=1 donor) consisting of human hepatocytes co-cultured with non-parenchymal cells (NPC). In contrast, only 5/12 DILI-compounds were correctly identified 2h following a single exposure to pooled human hepatocytes in suspension. Exposure of the 2D-sandwich culture human hepatocyte monocultures (2D-sw) for 3days resulted in the correct identification of 11/12 DILI-positive compounds, whereas exposure of the human 3D-MT co-cultures for 14days resulted in identification of 9/12 DILI-compounds; in addition to ximelagatran (also not identified by 2D-sw monocultures, Sison-Young et al., 2016), the 3D-MT co-cultures failed to detect amiodarone and bosentan. The sensitivity of the 2D human hepatocytes co-cultured with NPC to ximelagatran was increased in the presence of lipopolysaccharide (LPS), but only at high concentrations, therefore preventing its classification as a DILI positive compound. In conclusion (1) despite suspension human hepatocytes having the greatest metabolic capacity in the short term, they are the least predictive of clinical DILI across the MIP-DILI test compounds, (2) longer exposure periods than 72h of human hepatocytes do not allow to increase DILI-prediction rate, (3) co-cultures of human hepatocytes with NPC, in the presence of LPS during the 72h exposure period allow the assessment of innate immune system involvement of a given drug.
Asunto(s)
Microambiente Celular/efectos de los fármacos , Criopreservación , Evaluación Preclínica de Medicamentos/métodos , Drogas en Investigación/efectos adversos , Hepatocitos/efectos de los fármacos , Células 3T3 , Animales , Técnicas de Cultivo Celular por Lotes , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Técnicas de Cocultivo , Drogas en Investigación/metabolismo , Hepatocitos/citología , Hepatocitos/metabolismo , Humanos , Inmunidad Innata/efectos de los fármacos , Cinética , Macrófagos del Hígado/citología , Macrófagos del Hígado/efectos de los fármacos , Macrófagos del Hígado/inmunología , Lipopolisacáridos/agonistas , Lipopolisacáridos/antagonistas & inhibidores , Lipopolisacáridos/toxicidad , Ratones , Modelos Moleculares , Células del Estroma/citología , Células del Estroma/efectos de los fármacos , Células del Estroma/fisiologíaRESUMEN
Transfer of knowledge along the different phases of drug development is a fundamental process in pharmaceutical research. In particular, cross-species extrapolation between different laboratory animals and further on to first-in-human trials is challenging because of the uncertain comparability of physiological processes. Physiologically based pharmacokinetic (PBPK) modeling allows translation of mechanistic knowledge from one species to another by specifically considering physiological and biochemical differences in between. We here evaluated different knowledge-driven approaches for cross-species extrapolation by systematically incorporating specific model parameter domains of a target species into the PBPK model of a reference species. Altogether, 15 knowledge-driven approaches were applied to murine and human PBPK models of 10 exemplary drugs resulting in 300 different extrapolations. Statistical analysis of the quality of the different extrapolations revealed not only species-specific physiology as the key determinant in cross-species extrapolation but also identified a synergistic effect when considering both kinetic rate constants and gene expression profiles of relevant enzymes and transporters. Moreover, we show that considering species-specific physiology, plasma protein binding, enzyme and transport kinetics, as well as tissue-specific gene expression profiles in PBPK modeling increases accuracy of cross-species extrapolations and thus supports first-in-human trials based on prior preclinical knowledge.
Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Drogas en Investigación/farmacocinética , Regulación de la Expresión Génica/efectos de los fármacos , Hígado/efectos de los fármacos , Modelos Biológicos , Farmacología Clínica/métodos , Fisiología Comparada/métodos , Animales , Células Cultivadas , Biología Computacional , Sistema Enzimático del Citocromo P-450/genética , Sistema Enzimático del Citocromo P-450/metabolismo , Drogas en Investigación/metabolismo , Drogas en Investigación/farmacología , Perfilación de la Expresión Génica , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Alemania , Humanos , Hígado/citología , Hígado/enzimología , Hígado/metabolismo , Ratones Endogámicos C57BL , Especificidad de Órganos , Especificidad de la Especie , Organismos Libres de Patógenos EspecíficosRESUMEN
In this paper, an ex vivo model for the study of the transcorneal permeation of drugs, based on porcine tissues, was evaluated. The setup is characterized by ease of realization, absence of O2 and CO2 bubbling and low cost; additionally, the large availability of porcine tissue permits a high throughput. Histological images showed the comparability between porcine and human corneas and confirmed the effectiveness of the isolation procedure. A new de-epithelization procedure based on a thermal approach was also set up to simulate cornea permeability in pathological conditions. The procedure did not affect the integrity of the underlying layers and allowed the characterization of the barrier properties of epithelium and stroma. Six compounds with different physicochemical properties were tested: fluorescein, atenolol, propranolol, diclofenac, ganciclovir and lidocaine. The model highlighted the barrier function played by epithelium toward the diffusion of hydrophilic compounds and the permselectivity with regard to more lipophilic molecules. In particular, positively charged compounds showed a significantly higher transcorneal permeability than negatively charged compounds. The comparability of results with literature data supports the goodness and the robustness of the model, especially taking into account the behavior of fluorescein, which is generally considered a marker of tissue integrity.
Asunto(s)
Córnea/metabolismo , Evaluación Preclínica de Medicamentos/métodos , Drogas en Investigación/metabolismo , Ensayos Analíticos de Alto Rendimiento , Modelos Biológicos , Absorción Ocular , Mataderos , Administración Oftálmica , Animales , Fenómenos Químicos , Córnea/citología , Sustancia Propia/citología , Sustancia Propia/metabolismo , Drogas en Investigación/administración & dosificación , Drogas en Investigación/análisis , Drogas en Investigación/química , Epitelio Corneal/fisiología , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Técnicas In Vitro , Cinética , Permeabilidad , Especificidad de la Especie , Sus scrofaRESUMEN
NSC-743380 (1-[(3-chlorophenyl)-methyl]-1H-indole-3-carbinol) is in early stages of development as an anticancer agent. Two metabolites reflect sequential conversion of the carbinol functionality to a carboxaldehyde and the major metabolite, 1-[(3-chlorophenyl)-methyl]-1H-indole-3-carboxylic acid. In an exploratory toxicity study in rats, NSC-743380 induced elevations in liver-associated serum enzymes and biliary hyperplasia. Biliary hyperplasia was observed 2 days after dosing orally for 2 consecutive days at 100mg/kg/day. Notably, hepatotoxicity and biliary hyperplasia were observed after oral administration of the parent compound, but not when major metabolites were administered. The toxicities of a structurally similar but pharmacologically inactive molecule and a structurally diverse molecule with a similar efficacy profile in killing cancer cells in vitro were compared to NSC-743380 to explore scaffold versus target-mediated toxicity. Following two oral doses of 100mg/kg/day given once daily on two consecutive days, the structurally unrelated active compound produced hepatic toxicity similar to NSC-743380. The structurally similar inactive compound did not, but, lower exposures were achieved. The weight of evidence implies that the hepatotoxicity associated with NSC-743380 is related to the anticancer activity of the parent molecule. Furthermore, because biliary hyperplasia represents an unmanageable and non-monitorable adverse effect in clinical settings, this model may provide an opportunity for investigators to use a short-duration study design to explore biomarkers of biliary hyperplasia.
Asunto(s)
Enfermedad Aguda , Enfermedades de las Vías Biliares/inducido químicamente , Sistema Biliar/efectos de los fármacos , Indoles/efectos adversos , Administración Oral , Animales , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Antineoplásicos/metabolismo , Antineoplásicos/farmacocinética , Sistema Biliar/metabolismo , Sistema Biliar/patología , Enfermedades de las Vías Biliares/sangre , Enfermedades de las Vías Biliares/metabolismo , Enfermedades de las Vías Biliares/patología , Biomarcadores/sangre , Biotransformación , Enfermedad Hepática Inducida por Sustancias y Drogas/sangre , Enfermedad Hepática Inducida por Sustancias y Drogas/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Enfermedad Hepática Inducida por Sustancias y Drogas/fisiopatología , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Drogas en Investigación/administración & dosificación , Drogas en Investigación/efectos adversos , Drogas en Investigación/metabolismo , Drogas en Investigación/farmacocinética , Hiperplasia , Indoles/administración & dosificación , Indoles/sangre , Indoles/metabolismo , Indoles/farmacocinética , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Hígado/fisiopatología , Masculino , Distribución Aleatoria , Ratas Endogámicas F344 , Relación Estructura-ActividadRESUMEN
The emergence and spread of carbapenemase-producing Enterobacteriaceae is an important and very concerning problem. There is an urgent need of new antibimicrobials for treating these infections. Currently there are some options in the pipeline. Several new beta-lactamase and carbapenemase inhibitors as avibactam and MK-7655, combined with old or new betalactams are a very interesting option. Some combinations as ceftazidime-avibactam are in the late stages of clinical development and could reach the market in the next years. New aminoglycosides as plazomicin, tetracycline derivates as eravacycline, and several other new molecules as monosulfactams are currently in different stages of development.
Asunto(s)
Antibacterianos/uso terapéutico , Proteínas Bacterianas/metabolismo , Farmacorresistencia Bacteriana Múltiple , Drogas en Investigación/uso terapéutico , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Enterobacteriaceae/enzimología , Resistencia betalactámica , beta-Lactamasas/metabolismo , Antibacterianos/metabolismo , Antibacterianos/farmacología , Proteínas Bacterianas/antagonistas & inhibidores , Proteínas Bacterianas/genética , Carbapenémicos/metabolismo , Carbapenémicos/uso terapéutico , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Farmacorresistencia Bacteriana Múltiple/genética , Quimioterapia Combinada , Drogas en Investigación/metabolismo , Drogas en Investigación/farmacología , Enterobacteriaceae/efectos de los fármacos , Enterobacteriaceae/genética , Infecciones por Enterobacteriaceae/epidemiología , Infecciones por Enterobacteriaceae/microbiología , Predicción , Humanos , Resistencia betalactámica/genética , beta-Lactamasas/genéticaRESUMEN
The development of imatinib, an ATP-competitive inhibitor of the BCR-ABL oncoprotein, has revolutionized the treatment of chronic myelogenous leukemia (CML). Unfortunately, the leukemia eventually becomes resistant imatinib as a result of emergence of cells expressing drug insensitive BCR-ABL mutant proteins. This has motivated the development of several next-generation ATP-competitive drugs. This chapter describes the discovery and development of a complementary strategy involving inhibiting BCR-ABL by targeting an allosteric binding site. Compounds that bind to the myristate-binding pocket of BCR-ABL are able to induce formation of an "inactive" state and are able to overcome resistance mutations located in the ATP-binding pocket including the recalcitrant T315I "gatekeeper" mutation. Myristate-pocket inhibitors are also able to function synergistically with ATP-competitive inhibitors in cellular and murine models of CML and this dual inhibitory strategy is currently being investigated in the clinic.
Asunto(s)
Descubrimiento de Drogas , Drogas en Investigación/farmacología , Proteínas de Fusión bcr-abl/antagonistas & inhibidores , Modelos Moleculares , Inhibidores de Proteínas Quinasas/farmacología , Adenosina Trifosfato/antagonistas & inhibidores , Adenosina Trifosfato/química , Adenosina Trifosfato/metabolismo , Regulación Alostérica , Animales , Sitios de Unión , Unión Competitiva , Dominio Catalítico , Evaluación Preclínica de Medicamentos , Drogas en Investigación/química , Drogas en Investigación/metabolismo , Proteínas de Fusión bcr-abl/química , Proteínas de Fusión bcr-abl/metabolismo , Humanos , Ligandos , Conformación Molecular , Ácido Mirístico/antagonistas & inhibidores , Ácido Mirístico/química , Ácido Mirístico/metabolismo , Inhibidores de Proteínas Quinasas/química , Inhibidores de Proteínas Quinasas/metabolismoRESUMEN
Multidrug resistance (MDR) is a major obstacle to successful cancer chemotherapy. One of the main underlying mechanisms of this resistance is the over-expression of P-glycoprotein (P-gp), an ATP-dependent transmembrane transporter protein encoded by the MDR1 gene. P-gp might transport anti-cancer drugs out of cancer cells and decrease effective intracellular drug concentrations. An effective approach to overcome MDR is to inhibit the function of P-gp or its expression on the surface of cancer cells. Thus, application of MDR reversal agents can be seen as a potentially important means by which to overcome the clinical drug resistance of tumour cells and improve the efficacy of chemotherapy. Recently, research efforts worldwide have focused on reversal mechanisms for MDR and on the identification of reversal agents. Chinese scholars have performed a great deal of exploratory work by screening for efficacy and low toxicity in drug resistance reversal compounds. These compounds may provide more lead compounds with greater activity, leading to the development of more effective therapies for MDR cancer cells. In this review, the function and efficiency of novel compounds derived from traditional Chinese medicines are described (AU)
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Quimioterapia/tendencias , Quimioterapia , Quimioterapia/métodos , Drogas en Investigación/administración & dosificación , Drogas en Investigación , Drogas en Investigación/metabolismo , Medicina Tradicional ChinaRESUMEN
PURPOSE: This study evaluated the preclinical pharmacokinetics (PK) and disposition of fruquintinib (HMPL-013), a small molecule vascular endothelial growth factor receptors inhibitor. METHODS: In vitro and in vivo PK/ADME assays were conducted. Allometry and PK modeling/simulation were conducted to predict human PK parameters and the time course profiles. RESULTS: HMPL-013 has high permeability without efflux. It shows moderate oral bioavailability of 42-53 % and Tmax < 4 h in mouse, rat, dog and monkey, with exposure-dose linearity proved in rats and dogs. No significant food effect is on dog PK. HMPL-013 has moderately high tissue distribution. It majorly distributes in gastrointestinal tract, liver, kidney, adrenal and adipose. The plasma protein binding fraction is 88-95 % in mouse, rat, dog and human, invariable up to 10 µM. The in vivo clearance of HMPL-013 is low, consistent with the in vitro scaling. Three major oxidative metabolites were identified in liver microsomes of mouse, rat, dog, monkey and human. Dog is mostly similar to human regarding in vitro metabolism. Demethylation, hydroxylation and sequential glucuronidation are the major in vivo metabolic reactions. Direct urinary and biliary excretion of HMPL-013 is negligible. Metabolizing to M1 (demethylation), sequentially glucuronidating, followed by biliary excretion, and to a less extent, by urinary excretion, are important elimination pathways for HMPL-013 in rats. HMPL-013 has low risk of drug-drug interaction. It is predicted to have favorable human PK properties and low efficacious dose. CONCLUSION: HMPL-013 demonstrates good preclinical PK and enables successful human PK and dose projection. It is valuable for further clinical development.
Asunto(s)
Inhibidores de la Angiogénesis/farmacocinética , Benzofuranos/farmacocinética , Drogas en Investigación/farmacocinética , Absorción Intestinal , Microsomas Hepáticos/metabolismo , Modelos Biológicos , Inhibidores de Proteínas Quinasas/farmacocinética , Quinazolinas/farmacocinética , Receptores de Factores de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Inhibidores de la Angiogénesis/administración & dosificación , Inhibidores de la Angiogénesis/metabolismo , Inhibidores de la Angiogénesis/farmacología , Animales , Benzofuranos/administración & dosificación , Benzofuranos/metabolismo , Benzofuranos/farmacología , Bilis/química , Disponibilidad Biológica , Células CACO-2 , Células Cultivadas , Inhibidores Enzimáticos del Citocromo P-450 , Sistema Enzimático del Citocromo P-450/metabolismo , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Interacciones Farmacológicas , Drogas en Investigación/administración & dosificación , Drogas en Investigación/metabolismo , Drogas en Investigación/farmacología , Femenino , Interacciones Alimento-Droga , Humanos , Inactivación Metabólica , Masculino , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/enzimología , Inhibidores de Proteínas Quinasas/administración & dosificación , Inhibidores de Proteínas Quinasas/metabolismo , Inhibidores de Proteínas Quinasas/farmacología , Quinazolinas/administración & dosificación , Quinazolinas/metabolismo , Quinazolinas/farmacología , Distribución AleatoriaRESUMEN
N1-Benzylated dihydroquinolin-6-ols and their corresponding esters display exceptional activity against African trypanosomes in vitro, and administration of members of this class of compounds to trypanosome-infected mice results in cures in a first-stage African trypanosomiasis model. Since a quinone imine intermediate has been implicated in the antiparasitic mechanism of action of these compounds, evaluation of the hepatotoxic, mutagenic, and methemoglobin-promoting effects of these agents was performed. 1-Benzyl-1,2-dihydro-2,2,4-trimethylquinolin-6-ol hydrochloride and 1-benzyl-1,2-dihydro-2,2,4-trimethylquinolin-6-yl acetate showed outstanding in vitro selectivity for Trypanosoma brucei compared to the HepG2, Hep3B, Huh7, and PLC5 hepatocyte cell lines. 1-Benzyl-1,2-dihydro-2,2,4-trimethylquinolin-6-ol hydrochloride and 1-(2-methoxybenzyl)-1,2-dihydro-2,2,4-trimethylquinolin-6-yl acetate were not mutagenic when screened in the Ames assay, with or without metabolic activation. The latter 2 compounds promoted time- and dose-dependent formation of methemoglobin when incubated in whole human blood, but such levels were below those typically required to produce symptoms of methemoglobinemia in humans. Although compounds capable of quinone imine formation require careful evaluation, these in vitro studies indicate that antitrypanosomal dihydroquinolines merit further study as drug candidates against the neglected tropical disease human African trypanosomiasis.
Asunto(s)
Acetatos/efectos adversos , Drogas en Investigación/efectos adversos , Hepatocitos/efectos de los fármacos , Metahemoglobina/metabolismo , Quinolinas/efectos adversos , Compuestos de Quinolinio/efectos adversos , Tripanocidas/efectos adversos , Acetatos/metabolismo , Acetatos/farmacología , Activación Metabólica , Animales , Línea Celular , Supervivencia Celular/efectos de los fármacos , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Drogas en Investigación/síntesis química , Drogas en Investigación/metabolismo , Drogas en Investigación/farmacología , Hemoglobinas/química , Hemoglobinas/metabolismo , Hepatocitos/enzimología , Hepatocitos/metabolismo , Humanos , Concentración 50 Inhibidora , Cinética , Metahemoglobina/química , Pruebas de Mutagenicidad , Oxidación-Reducción , Quinolinas/síntesis química , Quinolinas/metabolismo , Quinolinas/farmacología , Compuestos de Quinolinio/metabolismo , Compuestos de Quinolinio/farmacología , Ratas , Tripanocidas/síntesis química , Tripanocidas/metabolismo , Tripanocidas/farmacología , Trypanosoma brucei brucei/efectos de los fármacos , Trypanosoma brucei brucei/crecimiento & desarrolloRESUMEN
Nucleoside reverse transcriptase inhibitors (NRTIs)/nucleotide reverse transcriptase inhibitors are key components of combination antiretroviral therapy for HIV infection. First-generation NRTIs are associated with mitochondrial toxicity in patients, mainly due to inhibition of human DNA polymerase γ (hDNA polγ) that manifests as adverse events such as lipodystrophy, lactic acidosis, myopathy, cardiomyopathy, or nephropathy in patients. In chronic nonclinical studies in rodents and nonrodents, eukaryotic (host) mitochondrial toxicity manifests as some drug-specific toxicities similar to human toxicity. BMS-986001, a novel thymidine analog with minimal hDNA polγ inhibition, has demonstrated antiretroviral activity in early clinical studies. The primary toxicity of BMS-986001 in rats and monkeys is bone marrow dyserythropoiesis with associated decreases in red blood cell mass. Additionally, at high doses, severe platelet reductions accompanied by cutaneous petechiae began during weeks 8 and 11 in 3 of 60 monkeys in chronic toxicity studies. In a 6-month study, platelet reductions required euthanasia of the 2 affected monkeys (300 mg/kg/d) at week 14, but with dose reduction (200 mg/kg/d) remaining monkeys had no platelet changes. One affected monkey (200 mg/kg/d) in a 9-month study completed dosing and its platelet counts recovered during a 1-month recovery. Formation of platelet-bound immunoglobulin in the presence of BMS-986001, together with rapid and complete platelet recovery in the absence of BMS-986001, suggested that platelet decreases in monkeys may be immune mediated. No findings indicative of mitochondrial toxicity were observed in rats or monkeys given BMS-986001, suggesting an improved safety profile compared to marketed NRTI or tenofovir disoproxil fumarate.
Asunto(s)
Anemia Macrocítica/inducido químicamente , Fármacos Anti-VIH/efectos adversos , Drogas en Investigación/efectos adversos , Púrpura Trombocitopénica/inducido químicamente , Inhibidores de la Transcriptasa Inversa/efectos adversos , Timidina/análogos & derivados , Anemia Macrocítica/sangre , Anemia Macrocítica/metabolismo , Anemia Macrocítica/patología , Animales , Fármacos Anti-VIH/administración & dosificación , Fármacos Anti-VIH/sangre , Fármacos Anti-VIH/metabolismo , Biotransformación , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Drogas en Investigación/administración & dosificación , Drogas en Investigación/metabolismo , Eritropoyesis/efectos de los fármacos , Femenino , VIH-1/efectos de los fármacos , VIH-1/crecimiento & desarrollo , Semivida , Macaca fascicularis , Masculino , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Mitocondrias/patología , Púrpura Trombocitopénica/inmunología , Púrpura Trombocitopénica/metabolismo , Púrpura Trombocitopénica/patología , Distribución Aleatoria , Ratas Sprague-Dawley , Inhibidores de la Transcriptasa Inversa/administración & dosificación , Inhibidores de la Transcriptasa Inversa/sangre , Inhibidores de la Transcriptasa Inversa/metabolismo , Análisis de Supervivencia , Timidina/administración & dosificación , Timidina/efectos adversos , Timidina/sangre , Timidina/metabolismo , Pruebas de Toxicidad Crónica , ToxicocinéticaRESUMEN
Transporter proteins are known to play a critical role in affecting the overall absorption, distribution, metabolism, and excretion characteristics of drug candidates. In addition to efflux transporters (P-gp, BCRP, MRP2, etc.) that limit absorption, there has been a renewed interest in influx transporters at the renal (OATs, OCTs) and hepatic (OATPs, BSEP, NTCP, etc.) organ level that can cause significant clinical drug-drug interactions (DDIs). Several of these transporters are also critical for hepatobiliary disposition of bilirubin and bile acid/salts, and their inhibition is directly implicated in hepatic toxicities. Regulatory agencies took action to address transporter-mediated DDI with the goal of ensuring drug safety in the clinic and on the market. To meet regulatory requirements, advanced bioassay technology and automation solutions were implemented for high-throughput transporter screening to provide structure-activity relationship within lead optimization. To enhance capacity, several functional assay formats were miniaturized to 384-well throughput including novel fluorescence-based uptake and efflux inhibition assays using high-content image analysis as well as cell-based radioactive uptake and vesicle-based efflux inhibition assays. This high-throughput capability enabled a paradigm shift from studying transporter-related issues in the development space to identifying and dialing out these concerns early on in discovery for enhanced mechanism-based efficacy while circumventing DDIs and transporter toxicities.
Asunto(s)
Descubrimiento de Drogas , Drogas en Investigación/farmacología , Ensayos Analíticos de Alto Rendimiento , Proteínas de Transporte de Membrana/metabolismo , Transporte Biológico/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Aprobación de Drogas , Evaluación Preclínica de Medicamentos , Interacciones Farmacológicas , Drogas en Investigación/química , Drogas en Investigación/metabolismo , Colorantes Fluorescentes , Humanos , Riñón/efectos de los fármacos , Riñón/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Proteínas de Transporte de Membrana/química , Relación Estructura-ActividadRESUMEN
For future targeted screening in National Residue Control Programmes, the metabolism of seven SARMs, from the arylpropionamide and the quinolinone classes, was studied in vitro using S9 bovine liver enzymes. Metabolites were detected and identified with ultra-performance liquid chromatography (UPLC) coupled to time-of-flight mass spectrometry (ToF-MS) and triple quadrupole mass spectrometry (QqQ-MS). Several metabolites were identified and results were compared with literature data on metabolism using a human cell line. Monohydroxylation, nitro-reduction, dephenylation and demethylation were the main S9 in vitro metabolic routes established. Next, an in vivo study was performed by oral administration of the arylpropionamide ostarine to a male calf and urine samples were analysed with UPLC-QToF-MS. Apart from two metabolites resulting from hydroxylation and dephenylation that were also observed in the in vitro study, the bovine in vivo metabolites of ostarine resulted in glucuronidation, sulfation and carboxylation, combined with either a hydroxylation or a dephenylation step. As the intact mother compounds of all SARMs tested are the main compounds present after in vitro incubations, and ostarine is still clearly present in the urine after the in vivo metabolism study in veal calves, the intact mother molecules were selected as the indicator to reveal treatment. The analytical UPLC-QqQ-MS/MS procedure was validated for three commercially available arylpropionamides according to European Union criteria (Commission Decision 2002/657/EC), and resulted in decision limits ranging from 0.025 to 0.05 µg l⻹ and a detection capability of 0.025 µg l⻹ in all cases. Adequate precision and intra-laboratory reproducibility (relative standard deviation below 20%) were obtained for all SARMs and the linearity was 0.999 for all compounds. This newly developed method is sensitive and robust, and therefore useful for confirmation and quantification of SARMs in bovine urine samples for residue control programmes and research purposes.
Asunto(s)
Antagonistas de Receptores Androgénicos/farmacocinética , Drogas en Investigación/farmacocinética , Microsomas Hepáticos/metabolismo , Drogas Veterinarias/farmacocinética , Acetamidas , Acetanilidas/metabolismo , Amidas/metabolismo , Amidas/farmacocinética , Amidas/orina , Aminofenoles , Antagonistas de Receptores Androgénicos/metabolismo , Antagonistas de Receptores Androgénicos/orina , Anilidas/metabolismo , Animales , Bovinos , Línea Celular , Evaluación Preclínica de Medicamentos/veterinaria , Estabilidad de Medicamentos , Drogas en Investigación/metabolismo , Humanos , Lactatos/metabolismo , Límite de Detección , Masculino , Fase I de la Desintoxicación Metabólica , Fase II de la Desintoxicación Metabólica , Nitrilos/metabolismo , Antiandrógenos no Esteroides/metabolismo , Antiandrógenos no Esteroides/farmacocinética , Antiandrógenos no Esteroides/orina , Quinolonas/metabolismo , Reproducibilidad de los Resultados , Especificidad de la Especie , Compuestos de Tosilo/metabolismo , Drogas Veterinarias/metabolismo , Drogas Veterinarias/orinaRESUMEN
One of the major reasons for late-stage failure of drug candidates is due to problems uncovered in pharmacokinetics during clinical trials. There is now a general consensus for earlier consideration of these effects in the drug discovery process. Computer-aided design technology provides us with tools to develop predictive models for such pharmacokinetic properties. Among these tools, we focus on pharmacophore modeling techniques in this article. Pharmacophore models that are reported for various cytochrome P450 (CYP) enzymes are reviewed for the isoenzymes CYP1A2, 2B6, 2C9, 2C19, 2D6, 2E1, and 3A4. In addition pharmacophore models for related metabolic processes through CYP19 (aromatase), CYP51 (14.α-lanosterol demethylase), PXR (pregnane X-receptor), and finally for human intrinsic clearance are also reviewed. The models reported by various scientists are schematically represented in the figures in order to visually demonstrate their similarities and differences. The models developed by different researchers or sometimes even by the same research group for different sets of ligands, provide a clear picture of the challenges in coming up with a single model with good predictive values. One of the main reasons for this challenge is related to relatively large size of the active sites and flexibility of the CYP isoenzymes, which results in multiple binding sites. We propose development of multiple- diverse pharmacophore models for each binding mode (as opposed to a single predictive model for each CYP isoenzyme). After scoring and prioritization of the models, we propose the use of a battery of pharmacophore models for each CYP isoenzyme binding mode to computationally obtain a P450 interaction profile for drug candidates early in the drug development cycle, when decisions on their fate can be made before incurring the costs of synthesis and testing.
Asunto(s)
Diseño Asistido por Computadora , Sistema Enzimático del Citocromo P-450/química , Evaluación Preclínica de Medicamentos/métodos , Drogas en Investigación/química , Drogas en Investigación/metabolismo , Receptores de Esteroides/química , Sitios de Unión , Sistema Enzimático del Citocromo P-450/metabolismo , Diseño de Fármacos , Interacciones Farmacológicas , Drogas en Investigación/farmacocinética , Pruebas de Enzimas , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Isoenzimas/química , Isoenzimas/metabolismo , Modelos Moleculares , Receptor X de Pregnano , Relación Estructura-Actividad Cuantitativa , Receptores de Esteroides/metabolismo , Electricidad EstáticaRESUMEN
The aim of this study is to further validate the use of ultrafiltration (UF) as a method for determining plasma protein binding (PPB) by demonstrating that non-specific binding (NSB) is not a limitation, even for highly lipophilic compounds, because NSB sites on the apparatus are passivated in the presence of plasma. Mass balance theory was used to calculate recovery of 20 commercial and seven investigational compounds during ultrafiltration in the presence and absence of plasma. PPB was also measured using this mass balance approach for comparison to PPB determined by rapid equilibrium dialysis (RED) and as found in the literature. Compound recovery during UF was dramatically different in the presence and absence of plasma for compounds with high NSB in PBS only. A comparison of PPB calculated by ultrafiltration with literature values or calculated by RED gave concordant results. Discrepancies could be explained by changes in pH, insufficient time to equilibrium, or compound instability during RED, problems which were circumvented by ultrafiltration. Therefore, NSB, as measured by the traditional incubation of compound in PBS, need not be an issue when choosing UF as a PPB assay method. It is more appropriate to calculate compound recovery from the device in plasma as measured by mass balance to determine the suitability of the method for an individual compound. The speed with which UF can be conducted additionally avoids changes in pH or compound loss that can occur with other methods. The mass balance approach to UF is thus a preferred method for rapid determination of PPB.
Asunto(s)
Proteínas Sanguíneas/metabolismo , Evaluación Preclínica de Medicamentos/métodos , Drogas en Investigación/metabolismo , Algoritmos , Animales , Sitios de Unión/efectos de los fármacos , Fenómenos Químicos , Diálisis , Estabilidad de Medicamentos , Drogas en Investigación/química , Humanos , Concentración de Iones de Hidrógeno , Interacciones Hidrofóbicas e Hidrofílicas , Cinética , Ratones , Unión Proteica , UltrafiltraciónRESUMEN
The membrane phospholipid affinity data, log k(w)(IAM), for 18 acidic and unionized drugs spanning a wide lipophilicity range were measured by HPLC on two different phospholipid stationary phases, i.e. IAM.PC.MG and IAM.PC.DD2. These data related weakly with both log P(N) values, the n-octanol/water partition coefficients of the neutral forms, and log D(7.4) values, the n-octanol/water partition coefficients of the mixtures of neutral and ionized forms at pH 7.4. The lack of collinearity confirms that, differently from partition in n-octanol/water, partition in phospholipids encodes not only lipophilic/hydrophobic intermolecular recognition forces but also ionic bonds, due to electrostatic interactions between electrically charged species and phospholipids, according to the "pH piston hypothesis". Since, differently from bases, electrostatic interactions between acids and phospholipids take place at the surface of phospholipid layers (choline moieties), and not near their lipophilic core (phosphate moieties), they were parameterized by a new procedure yielding "Δ'log k(w)(IAM)" parameters, i.e. the difference between the IAM retention factors observed for the analytes and those of neutral compounds with the same n-octanol partition values displayed by the analytes at pH 7.4. All acidic analytes, but one, and all unionized analytes, but the unionizable ones, showed positive Δ'log k(w)(IAM) values, indicating that they partition stronger in phospholipids than in n-octanol. Log BB values (capability to pass BBB) weakly related with both lipophilicity and phospholipid affinity values; in contrast they are inversely related with Δ'log k(w)(IAM) values. The relationships between log BB and Δ'log k(w)(IAM) practically overlapped the previously found log BB/Δlog k(w)(IAM) relationships for bases. The excess of polar interaction component between acidic drugs and phospholipids, mainly electrostatic forces, although enhancing partition in phospholipids, hinders membrane passage, analogously to the behavior previously reported for bases. The study suggests that IAM-HPLC is an effective technique to perform simple and fast measurements of the intermolecular recognition forces related to membrane partition and permeation. This can contribute to better understand the mechanisms governing both partition of charged species in cell membranes and passage through them, also allowing the possible optimization of the pharmacokinetic properties of the drugs at the early stages of their development.
Asunto(s)
Barrera Hematoencefálica/metabolismo , Membrana Celular/química , Evaluación Preclínica de Medicamentos/métodos , Drogas en Investigación/química , Drogas en Investigación/farmacocinética , Modelos Biológicos , Fosfolípidos/química , Animales , Membrana Celular/metabolismo , Cromatografía Líquida de Alta Presión , Drogas en Investigación/metabolismo , Humanos , Concentración de Iones de Hidrógeno , Interacciones Hidrofóbicas e Hidrofílicas , Membranas Artificiales , Permeabilidad , Fosfolípidos/metabolismoRESUMEN
Piplartine (piperlongumine, 5,6-dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-2(1H)-pyridinone) is a biologically active alkaloid/amide from peppers, as from long pepper (Piper longum L. - Piperaceae). Long pepper is one of the most widely used in Ayurvedic medicine, which is used to treat many diseases, including tumors. The purpose of the current paper is to address to the chemical structure establishment and to systematically survey the published articles and highlight recent advances in the knowledge of the therapeutic potential of piplartine, establishing new goals for future research. The reported pharmacological activities of piplartine include cytotoxic, genotoxic, antitumor, antiangiogenic, antimetastatic, antiplatelet aggregation, antinociceptive, anxiolytic, antidepressant, anti-atherosclerotic, antidiabetic, antibacterial, antifungal, leishmanicidal, trypanocidal, and schistosomicidal activities. Among the multiple pharmacological effects of piplartine, its anticancer property is the most promising. Therefore, the preclinical anticancer potential of piplartine has been extensively investigated, which recently resulted in one patent. This compound is selectively cytotoxic against cancer cells by induction of oxidative stress, induces genotoxicity, as an alternative strategy to killing tumor cells, has excellent oral bioavailability in mice, inhibits tumor growth in mice, and presents only weak systemic toxicity. In summary, we conclude that piplartine is effective for use in cancer therapy and its safety using chronic toxicological studies should be addressed to support the viability of clinical trials.
Asunto(s)
Antineoplásicos Fitogénicos/uso terapéutico , Drogas en Investigación/uso terapéutico , Neoplasias/tratamiento farmacológico , Piperidonas/uso terapéutico , Animales , Antineoplásicos Fitogénicos/metabolismo , Antineoplásicos Fitogénicos/farmacocinética , Antineoplásicos Fitogénicos/farmacología , Disponibilidad Biológica , Drogas en Investigación/metabolismo , Drogas en Investigación/farmacocinética , Drogas en Investigación/farmacología , Frutas/química , Humanos , Medicina Ayurvédica , Neoplasias/metabolismo , Patentes como Asunto , Piper/química , Piperidonas/metabolismo , Piperidonas/farmacocinética , Piperidonas/farmacologíaRESUMEN
The high rate of attrition during drug development and its associated high research and development (R&D) cost have put pressure on pharmaceutical companies to ensure that candidate drugs going to clinical testing have the appropriate quality such that the biological hypothesis could be evaluated. To help achieve this ambition, drug metabolism and pharmacokinetic (DMPK) science and increasing investment have been deployed earlier in the R&D process. To gain maximum return on investment, it is essential that DMPK concepts are both appropriately integrated into the compound design process and that compound selection is focused on accurate prediction of likely outcomes in patients. This article describes key principles that underpin the contribution of DMPK science for small-molecule research based on 15 years of discovery support in a major pharmaceutical company. It does not aim to describe the breadth and depth of DMPK science, but more the practical application for decision making in real-world situations.